The PIL, filed by advocate M L Sharma, sought action against Ranbaxy for allegedly supplying substandard and adulterated drugs D rug maker Ranbaxy Laboratories has maintained that all the drugs sold by the company in the Indian market were safe and effective. The statement came in the wake of a petition filed in the Supreme Court, on Friday, seeking cancellation of Ranbaxy's licence and a probe by Central Bureau of Investigation (CBI) into alleged supply of adulterated drugs in the country. Following the petition, the apex court issued notices to the Centre and the company. However, the company said it had not yet received any notice but would respond if it got one. "Ranbaxy has not yet received any notice to file reply from the Hon'ble Supreme Court of India. If the company receives a notice, it will respond appropriately to the observations," said a Ranbaxy spokesperson. The company also said it had complied with all the requirements under the Indian law.